Abstract Much of our current understanding of the pathogenic mechanisms in human neurodegenerative disorders has been derived from animal studies. As such, transgenic mouse models have signiWcantly contributed to the development of novel pathogenic concepts underlying human tauopathies, a group of diseases comprising various forms of neurodegenerative disorders including Alzheimer's disease, corticobasal degeneration, argyrophilic grain disease, progressive supranuclear palsy, and Pick's disease as well as hereditary fronto-temporal dementia with parkinsonism linked to chromosome 17. Here, we will review in vivo models of human tauopathies with particular preference to transgenic mouse models. Strengths and limitations of these models in recapitulating the complex pathogenesis of tauopathies will be discussed.
Introduction
Pathologic alterations in the microtubule-associated protein tau have been linked to the pathogenesis of a number of neurodegenerative disorders, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AgD), Pick's disease (PD), as well as a subset of hereditary frontotemporal dementias (FTDs), which are therefore also collectively classiWed as tauopathies [24, 49, 87] . In these diseases, the microtubule-associated protein tau accumulates, forming detergent-resistant intracellular inclusions known as neuroWbrillary tangles (NFTs). In AD, the temporal and spatial distribution of tau pathology correlates well with the clinical disease severity [9] . However, whether it acts as the primary culprit or is indirectly involved in the pathogenic pathways culminating in neuronal cell loss, is still hotly contested. Although pathogenic tau mutations have been identiWed in FTD with parkinsonism linked to chromosome 17 (FTDP-17T) which is clear evidence of tau dysfunction playing a pivotal role in neurodegeneration, the mechanism of tau dysfunction leading to neuronal demise is only poorly understood.
In many ways, human tauopathies represent a heterogeneous group of diseases, with aVected patients presenting with diverse clinico-pathological phenotypes ranging from prototypical aphasia to dementia syndromes. It is therefore of utmost importance to elucidate the mechanisms of tau accumulation and NFT formation in these diseases, and in particular to answer the question of whether all tauopathies develop through a unifying common pathogenic pathway. On the molecular level, the phenotypic diversity of tauopathies is attributable to diVerent types of tau gene mutations as well as additional modifying genetic and epigenetic factors. Whereas on the cellular level, not only neuronal but also glial cell elements can be aVected by tau-related pathology in locoregionally diVerent and disease-(and sometimes also stage-) speciWc patterns, heterogeneity on the biochemical level is reXected by the expression of diVerent tau isoforms. These isoforms arise through alternative splicing, yielding variants with diVerential binding to microtubules according to the presence of either three (3R isoforms) or four microtubule-binding repeat domains (4R isoforms). Homologous repeat sequences are also present in the microtubule-associated proteins MAP2 and MAP4. As a major microtubule-associated protein, mammalian tau is subject to extensive regulation on the transcriptional level and to post-translational modiWcation, in particular to phosphorylation, resulting in complex biochemical patterns [51] . Through binding to microtubules, tau is involved in the initiation and stabilization of these structures, which, in neurons, are critical for axonal transport and proper synaptic function [84] . Of particular note, overexpression of tau in neuronal cell lines as well as in primary neurons leads to disturbed kinesin-dependent traYcking of organelles along microtubule tracts [21, 86] . In particular, mitochondria fail to be transported to peripheral cell compartments, which may represent an important pathogenic mechanism for neurodegeneration [79] , contributing to the loss of synapses as an early event in AD pathogenesis [14, 83] .
In the adult human brain, six tau isoforms are expressed that are generated through alternative splicing [12, 23, 49] . These isoforms diVer by containing either three or four microtubule-binding domains within their C-termini (3R and 4R isoforms, respectively) with additional variability arising from the existence of none, one or two N-terminal inserts (0N, 1N, 2N isoforms). The 4R isoforms bind to microtubules more avidly than the 3R variants. Isoform expression patterns are developmentally regulated with the 3R variants being expressed during early life phases ("fetal tau") and it has therefore been hypothesized that expression of 3R tau might be associated with the higher degree of plasticity that is required during neuronal development [26] . Although in embryonic hippocampal slice cultures of tau-null mice an inhibition of neuronal maturation can be demonstrated [19] , tau-deWcient mice appear physiologically normal, are able to reproduce and do not develop obvious neurological phenotypes, presumably because other microtubule-associated proteins (such as MAP1A and 1B) can compensate for tau loss [31] .
For quite some time, interest in tau as an important pathogenic factor in AD-related neurodegeneration has lagged behind the research eVorts devoted to the amyloid beta peptide (A ), partly because tau pathology was commonly accepted to occur downstream of A according to the beta amyloid cascade hypothesis [32] . However, in various other tauopathies, prominent tau pathology develops in the absence of extracellular A deposits. In addition, the identiWcation of tau mutations underlying the pathogenesis of FTDP-17T [39, 68, 75] , a neurodegenerative FTD entity which follows an autosomal-dominant mode of inheritance, has sparked intense research eVorts aimed at the generation of animal models not only to decipher the role of tau in neurodegeneration but also at deriving novel therapeutic approaches for human tauopathies.
Remarkably, several crucial features of human tauopathies have been recapitulated in relatively simple organisms, such as Caenorhabditis elegans and Drosophila melanogaster. However, in these models many pathogenic aspects are overly simpliWed and therefore considerably limit the interpretation of Wndings in terms of drawing parallels to the pathogenic pathways at play in human tauopathies. Consequently, various tau transgenic (tg) mouse lines have been generated to closer model aspects of the very complex, multi-facet pathogenesis of human tauopathies. After brieXy summarizing selected Wndings in C. elegans and D. melanogaster, we will focus this review on the various tg mouse models that have been generated to experimentally recapitulate important histopathological, and sometimes also behavioral features of tauopathies.
Modeling tauopathies in C. elegans
Caenorhabditis elegans represents an easy to genetically manipulate model for the experimental characterization of normal gene function as well as for exploring pathogenic protein dysfunction. To model tauopathy disorders, several transgenic worm models have been generated [10, 46, 61] . Neuronal expression of normal and FTDP-17T associated mutant human tau proteins (P301L, V337M) [46] caused progressive uncoordinated locomotion, indicative of a nervous system defect, which culminated on day 9 with worms becoming nearly immobile. Moreover, expression of wildtype (wt) human tau was associated with a decreased life span [46] . Interestingly, the transgenic tau protein expressed in C. elegans was found to be phosphorylated at analogous residues as it occurs in human tauopathies [46] , an observation recently conWrmed independently [10] . Of note, whereas no neuronal degeneration was reported by the latter group, transgenic human tau was demonstrated to become highly phosphorylated and to assume a PHF-like conformation [10] . SigniWcantly, FTDP-17T mutant tau lines exhibit a more severe phenotype marked by the production of more detergent-insoluble tau and by a more severe axonal degeneration in comparison to wt-tau expressing lines [46] . In particular, in the line expressing the FTDP-17T-associated V337M tau mutation, the high level of insoluble tau was paralleled by extensive axonal degeneration [46] . Nerve cell degeneration, accompanied by tau-accumulation in cell bodies and neuronal processes, was recently also reported for another transgenic worm model where the P301L and R406W mutations were expressed in mechanosensory neurons [61] . Thus, the induced tau pathology in worms resembles the situation in human tauopathies in so far as there is progressive accumulation of hyperphosphorylated insoluble tau as well as neurodegeneration with one of the main diVerences being the absence of overt tau tangle formation in C. elegans. Nevertheless, in summary, these experiments provided evidence for at least a contributory (if not primary causal) role of tau in neurodegenerative processes and thus points to a high degree of evolutionary conservation in tau-associated pathogenesis.
Lessons from Drosophila
Bridging the simplicity of C. elegans and the complexity of vertebrate models, D. melanogaster has become an invaluable tool for the study of neurodegenerative diseases [6] . At least 50% of Drosophila genes have human homologs and more than 70% of human disease genes have Drosophila homologs, making the (rather primitive) Xy a relevant organism to model selected aspects of human diseases, including neurodegenerative disorders. Drosophila Xies possess one single tau gene, which is expressed in many types of neurons, where in analogy to mammalian neuronal cells, tau protein can also accumulate within axonal processes [33] . Wittmann et al. [95] have generated transgenic D. melanogaster Xies as a genetic model of tau-associated neurodegenerative disorders by expressing wt and mutant (R406W, V337M) forms of human tau which recapitulated key features of human tauopathies. Despite only moderate levels of transgene expression, transgenic Xies exhibited adult onset progressive neurodegeneration with a signiWcantly reduced life span, especially in the R406W tg Xy lines. With relative anatomic selectivity abnormal tau protein accumulated, but NFT formation was not observed. In summary, these results indicated that tau-induced neurodegeneration in Xies does occur in the absence of large tau Wlamentous aggregates [95] . Moreover, overexpression of the human tau homolog in Drosophila neurons induces apoptosis, which is not accompanied by the formation of intracellular NFTs [6, 22, 43] . This Wnding, which, prima vista, would argue against a signiWcant cytotoxic role of tau-rich NFTs, could reXect a mode of neurotoxicity which depends on protein alterations occurring prior to the assembly of Wbrillar aggregates such as on smaller proteolytic tau fragments, which-at least in the human system-were recently postulated to be pathogenically important by promoting aggregation through nucleation eVects [50, 67, 93] . However, when wt human tau (4R isoform) was coexpressed with the Xy homolog of glycogen synthase kinase-3beta (one of the known tauphosphorylating kinases) in another Drosophila model, NFTs were observed [43] . Thus, Drosophila tau models may faithfully replicate several important aspects of human tauopathies, including tau hyperphosphorylation, accumulation, and Wbril formation as well as neuronal degeneration.
Mouse models
A considerable number of mouse tauopathy models have been generated that not only recapitulated key histopathological hallmarks of tauopathies but, to a variable degree, also reproduced important behavioral aspects of the respective human disorders. Tauopathies are morphologically heterogeneous disorders, with neuronal and/or glial cell components aVected in rather disease-speciWc and sometimes stereotypic spatiotemporal patterns [24, 49, 87] . On the molecular level, it should be noted, that in contrast to the adult human brain only 4R variants of the murine tau homolog are endogenously expressed in the adult mouse brain. Furthermore, major AD-related phosphorylation sites of human tau are conserved in the murine protein, including those phosphorylated by the major tau kinases glycogen synthase-kinase 3 (GSK-3 ) and cyclin-dependent kinase 5 (CDK5), both of which also serve crucial roles during neurodevelopment [16, 17, 44] . Of note, with regard to AD pathogenesis, -amyloid has been shown to trigger tau phosphorylation by activating GSK-3 and CDK5 [44, 48] . It therefore seems that the mouse lends itself as a model organism to recapitulate essential aspects of tauopathies. However, as will be discussed below, extreme care needs to be exercised in the interpretation of histopathological Wndings and the results of behavioral tests. Depending on the promoter system chosen to drive transgene expression, the phenotypes of tg mouse models often diVer strikingly even if the very same transgene is expressed. Whereas, the murine thy-1 promoter favors transgene expression especially in brain stem and spinal cord (which consequently often results in an axonopathy-related pathology through the preferential aVection of the long Wber tracts), others such as the -calcium-calmodulin-dependent kinase-II (CaMK-II) promoter target expression predominantly to the forebrain giving rise to behavioral phenotypes. In addition, gene dosage eVects and altered ratios of expressed tau isoforms (i.e., 4R versus 3R variants) have to be taken into account. Furthermore, through the use of additional promoters, cell-type speciWc transgene expression (neuronal versus glial expression) can be achieved. Moreover, diVerent promoters yield variable transgene expression levels, which is extremely relevant as pathological protein aggregation including the assembly of Wbrillar protein deposits is concentration-dependent. Last but not least, as will be discussed in more detail below, phenotypes of tg mice show striking variance depending on whether transgene expression occurs in the murine endogenous or in a knockout background. Thus, currently existing tg mouse models can only recapitulate selected aspects of human tauopathies. With regard to the multiple molecular pathways that have so far been implicated with the rather complex pathogenesis of these diseases, it currently seems more than questionable whether the generation of mouse models which faithfully mirror the full human disease phenotypes will ever be achieved. Rather, a more realistic view seems that by carefully putting together the single pieces of information that are provided by each of the mouse models, a picture will emerge in the hopefully not too distant future that permits understanding the complex pathogenic pathways in tauopathies well enough to devise rationale, eVective and possibly individualized therapeutic approaches to combat these devastating diseases.
Models with tg expression of human wt tau isoforms (Table 1)

Modeling neuronal pathology
The initial mouse models for human tauopathies allowed only speciWc human tau isoforms to be studied within the background of endogenous wt murine tau. The Wrst tg mouse models were generated more than a decade ago, when pathogenic tau mutations had not yet been identiWed, by expressing the longest human brain tau isoform (4R/2N) under the control of the human thy-1 promoter [29] . The tg human tau protein was found to be expressed in neuronal cell bodies, axons and dendrites. Interestingly, the tg tau protein, expressed at rather low levels, was phosphorylated at the same sites that are hyperphosphorylated in the paired helical Wlaments in human AD brains. In the absence of NFTs this observed pathology [29] was therefore interpreted as a pre-tangle phenotype, to be considered as intracellular "precursor" lesion preceding the full-blown tau NFT pathology associated with tauopathies [3, 8] . In a similar mouse model where the human 4R/2N isoform was expressed under the control of the murine thy1 (thy-1.2, respectively) promoter, prominent somatodendritic tau expression and hyperphosphorylation was demonstrated [69, 77] (Fig. 1a, b ). These mice exhibited severe axonopathy with signs of Wallerian degeneration reXected by axonal breakdown and myelin sheath disintegration. Moreover, severe motor symptoms with neurogenic hindleg muscle atrophy, as histologically veriWed by the presence of grouped small angular muscle Wbers, developed in these animals [69, 77] .
In further models, alternative promoters such as the one for mouse prion protein (MoPrP) were used to control transgene expression which resulted in even more pronounced phenotypes. Two tg models, in which the shortest human brain isoform of tau (3R/0N) was expressed, were created [11, 41] . Brion et al. [11] , using a mouse model with rather low 3R tau transgene expression driven by the murine, house-keeping type HMG-CoA-reductase promoter, did not Wnd NFTs in mice younger than 19 months of age, but the tg protein was demonstrated to be phosphorylated at sites known from tau proteins of paired helical Wlaments. In contrast, using the MoPrP promoter to drive transgene expression, insoluble, hyperphosphorylated tau progressively accumulated and NFT-like argyrophilic intraneuronal inclusions consisting of tau-immunoreactive Wlaments were observed in these mice as early as at 6 months of age [41] . Due to high-transgene expression in spinal cord motor neurons, variable axonopathy with formation of tau-immunoreactive spheroids and histomorphological correlates of axonal degeneration was found. Of note, the tau inclusions, although stainable by the Bodian silver method, were not detectable by the Gallyas procedure, which detects most NFTs in human tauopathies [90] . Nevertheless, although formation of bona Wde NFTs was not observed (unless the mice reached a very old age [42] ), these were the Wrst tg mice to recapitulate key features of human tauopathies. The follow-up analysis of these mice at 12-24 months of age [42] revealed that the Wbrillary tau lesions had now converted into AD-like tangle structures detectable by the Gallyas silver impregnation method. The particular relevance of this model was that, for the Wrst time, an age-dependent maturation of tau inclusions culminating in the assembly of insoluble, Wlamentous, Gallyas-positive NFTs was experimentally recapitulated.
As pointed out earlier, the interpretation of these mouse models, while being valuable Wrst steps to explore the role of tau in neurodegeneration, was restricted by the fact that only one speciWc isoform of human tau was transgenically expressed. To avoid this caveat, alternative novel mouse models were created. DuV et al. [20] generated mice that overexpressed a human tau transgene containing not only the coding regions but also intronic as well as regulatory sequences. Thus, in these mice, all six human tau isoforms were expressed at the mRNA and protein level in the CNS but when compared to human brain the ratio of 3R:4R human tau isoforms diVered as relatively more 3R tau was present in these mouse brains. However, due to the presence of 4R endogenous murine tau there was no imbalance of the total 3R:4R ratio. Tau-positive axonal swellings developed in the spinal cords of the mice and correlated with a hind-limb abnormality, but no other neuropathological abnormalities, in particular no tangle formation, were seen [20] . In an even more sophisticated approach, Andorfer et al. [2] generated a tg mouse model that produces all six human tau isoforms in the absence of endogenous mouse (4R) tau, shifting the isoform ratio toward the 3R variants. Notably, these mice developed tau Wlaments by the age of 9 months, and pathological tau accumulated in cell bodies and neuronal dendrites in a spatiotemporal-relevant pattern. Resembling AD pathology, tau aggregation predominantly occurred in the neocortical neurons and pyramidal hippocampal cells, whereas brain stem and spinal cord were almost devoid of tau lesions. There was no [74, 85] evidence of signiWcant motor or behavioral abnormalities. Subsequently, Van Leuven and co-workers [85] established a mouse model where the human tau-4R/2N isoform was expressed in a tau-null background backcrossed into FVB/ N. These mice survive normally and display only a minor motor phenotype, which occurs late in life in the absence of tau aggregates [85] . Of note, also in contrast to 4R/2N tg mouse models with the endogenous mouse tau background [69, 77] no obvious pathology, in particular no axonopathy was observed [85] . Instead, in a very similar model of mice expressing the 4R/2N isoform in a murine tau-k.o. C57/ BL6 background analysis revealed signiWcant increases in hippocampal volume and neuron numbers with improved hippocampal memory retention [74] . It was concluded from this study that 4R-tau serves an important function during hippocampal development by controlling neuronal precursor proliferation and diVerentiation [74] . Interpreting the results of these tg models, the ensuing question of whether endogenous murine tau is inhibitory to tau Wlament formation, remains to be answered unambiguously. The large excess of wt human tau in most of these models suYces to induce mild "pre-tangle" pathology, marked by an abnormal non-Wlamentous accumulation of phosphorylated tau in cell bodies and dendrites with an associated axonopathy and variable motor symptoms. However, even with the use of strong promoters, high-level expression of wt tau iswith two exceptions [2, 42] -not suYcient to cause the formation of bona Wde NFTs as well as signiWcant neuronal losses. Remarkably, especially in light of the amyloid cascade hypothesis, this also holds true for mice that coexpress amyloid precursor protein (APP) harboring the Swedish and London mutations (APP 751SL ) and the presenilin-1 M146L mutant (PS1 M146L ) combined with the human 3R/ 0N wt tau transgene under control of a modiWed HMG-CoA reductase promoter [7] . Only when the human 3R isoform is expressed under control of the MoPrP promoter, few Gallyas-positive NFT-like structures are observed in mice aged 24 months [42] . Moreover, the Andorfer et al. study [2] recapitulated for the Wrst time tau hyperphosphorylation with formation of Wbrillary tau aggregates by transgenically expressing all six human tau isoforms in a murine tau-k.o. background.
Modeling glial pathology
While the tg mouse models discussed above strongly focused on studying tau in CNS neurons, the Wlamentous glial tau pathology characteristic of CBD, PSP, AgD, and most FTDP-17T cases had been neglected so far. Götz et al. [30] and Higuchi et al. [34] were the Wrst to report on tg mice that modeled tau-associated neurodegeneration of glial cells. When all three isoforms of human 3Rtau were expressed under the control of the mouse T 1 -tubulin promoter, Wlamentous, Gallyas-positive aggregates reminiscent of astrocytic plaques were observed whichalthough not speciWc-are considered rather typical lesions in CBD [13] . These lesions developed in older mice and no formation of tau aggregates was detected in neurons [34] . Furthermore, recapitulating typical Wndings in PSP, CBD, and AgD, Gallyas-positive, tau-immunoreactive oligodendroglial coiled body-like structures were found which correlated with an age-dependent accumulation of Wlamentous Fig. 1 a Abundant tau stained (phosphorylation-dependent anti-tau antibody AT8) pre-tangle neurons are observed in sector CA1 of a transgenic mouse strain expressing the longest human four-repeat tau isoform [64] . b Notably this pre-tangle pathology is not stained by the Gallyas silver technique. c AT8 stained neuroWbrillary tangles (NFT) in the brainstem region of a transgenic mouse strain expressing the human P301S mutation [1] . d In contrast to the pre-tangle pathology obtained in mouse strains expressing human wild-type tau isoforms NFT in P301S mice are strongly stained with Gallyas. Scale bar a-d: 100 m tau in degenerating oligodendroglial cells [34] . Thus, the formation of tau-positive glial lesions as they occur in certain human tauopathies can be modeled in transgenic mice. As will be discussed in the following section, FTDP-17T-associated tau mutants were also expressed using alternative glia-targeting promoters to model human glial tau pathology [30, 36] .
Models with tg expression of human mutant tau isoforms (Table 2)
Modeling neuronal pathology
Soon after the identiWcation in 1998 of pathogenic tau mutations in a subset of FTDP-17 families (reviewed in [92] ), various groups were successful in creating tg mouse models in which NFT formation was recapitulated in vivo. Both, neuronal [1, 27, 53, 80, 82] and glial tau Wlamentous pathologies [30, 36] were demonstrated. Tau gene mutations that underlie the pathogenesis of certain hereditary tauopathies such as FTDP-17T either occur near splice sites, changing ratios within the expressed tau isoform repertoire, or occur as missense mutations, both of which likely aVect the binding aYnity of tau toward microtubules. In the Wrst reported mouse model which successfully demonstrated the formation of NFTs, the human P301L mutation, which results in pronounced adverse eVects on microtubule-assembly promoting activity [4] , was expressed under the control of the MoPrP promoter [53] leading in homozygous mice to mutant human tau expression at a twofold level in comparison to endogenous murine levels. In homozygous mice, motor and behavioral deWcits related to NFT formation started to develop at 4.5 months with NFTs and Pick body-like neuronal lesions occurring in amygdala, mid-brain, brain stem and spinal cord, and with pre-tangle tau pathology in the neocortex, hippocampus, and basal ganglia. In addition to a signiWcant reduction of spinal cord motor neurons that almost reached 50%, a peripheral neuropathy accompanied by neurogenic muscle atrophy was observed. Biochemically, the presence of Gallyas-positive NFTs containing hyperphosphorylated tau was demonstrated. One of the signiWcant advances achieved through this model was that, for the Wrst time, a link between neuroWbrillary pathology and neuronal loss was established. Remarkably, a relatively low transgene expression level was suYcient to trigger Wbrillary tau aggregates. In contrast, previous mouse models with higher expression levels of the human wt tau transgene failed to cause NFT formation, which likely reXects the pathogenicity of P301L as the most common tau gene mutation associated with FTDP-17T (reviewed in [92] ). Expressing the same P301L transgene, however under the control of the murine thy-1.2 promoter, Götz et al. [27] similarly observed hyperphosphorylation of accumulated tau which appeared redistributed from its normal axonal localization to somatodendritic compartments. In addition, as demonstrated by electron microscopy, short Wlament formation occurred in the cortex, brain stem and spinal cord [27] . Likewise, using a very similar model controlled by the murine thy-1 promoter, wt human 4R/2N tau was expressed in one mouse strain comparatively to the P301L mutation [85] . Whereas in the wt tau mice motor symptoms were evident already at 6-8 weeks, no tau aggregates formed and the animals had a normal life span. In contrast, in the P301L transgene-expressing mice, progressive Wbrillary tau aggregation started to develop at around 6 months of age and, despite only minor motor problems, animals died prior to the age of 13 months [85] . Tangle-like tau pathology was also observed in mice that expressed the P301L mutation in combination with a tet-oV regulated CaMK-II promoter system [70, 72] . As expected, high-level P301L expressing mice developed pre-tangles as early as at 2.5 months of age, with rapid progression of tau pathology culminating both in NFT formation by around 4 months of age and marked cognitive impairment. NFTs were Wrst observed in the neocortex and, with increasing age, progressed to the hippocampus and the limbic system [70, 72] . Remarkably, when transgenic P301L expression was suppressed by administration of doxycycline, memory function was signiWcantly improved, but NFTs continued to accumulate, and a region-speciWc dissociation between neuronal loss and the occurrence of NFTs was veriWed [76] . This may also be related to a postulated dissociation between the mechanisms causing memory impairment and those leading to tau Wbrillation. It seems that in this model NFTs per se are not the primary cause of the observed cognitive deWcits [72] which may rather be reXections of a reversible neuronal dysfunction.
Interestingly, proteomic analyses of P301L tg mice revealed a mitochondrial dysfunction related to modiWcation in the expression patterns of mitochondrial respiratory chain complex components, antioxidant enzymes implicated in detoxiWcation of reactive oxygen species (ROS) and of synapse-associated proteins [18] . In the context of tauopathies, mitochondrial dysfunction has also independently been corroborated in vivo by several groups. For instance, chronic rotenone-mediated complex I inhibition is suYcient to trigger a cerebral tauopathy with tau accumulations occurring in neurons, astrocytes, and oligodendrocytes [38] .
In mice expressing the human P301S tau mutant associated with early onset FTDP-17T, two groups demonstrated neurodegeneration leading to nerve cell loss. In these models starting at 5-6 months, Wlamentous hyperphosphorylated tau pathology develops in brain stem and spinal cord with a signiWcant reduction of spinal cord motor neurons in [71] hAPP £ tau ¡/¡ homozygous mice in conjunction with severe paraparesis [1, 5, 97] (Fig. 1c, d ). Remarkably, Bellucci et al. [5] also reported on microglia activation-recently implicated in the clearance of A deposits (for review see [96] )-adjacent to tau-positive neurons. In an alternative model of FTDP-17T, the human V337M mutation that is weaker in comparison to the P301L mutation with regard to aVecting microtubuleassembly was expressed under the control of the PDGFpromoter. This resulted in the formation of tau-containing NFTs in the hippocampus and in various behavioral abnormalities [81] . Similarly, when the FTDP-17T-associated R406W mutation was expressed using the CaMK-II promoter, congophilic hyperphosphorylated tau inclusions formed in the forebrain starting at 18 months of age, with aged mice exhibiting an impaired associative memory but no signiWcant sensorimotor deWcits. Sarcosyl-insoluble tau was recovered from old tg mice only [82] . Expression of the same mutant, but under control of the Syrian hamster prion protein promoter, led to the development of Wlamentous tau aggregations in the hippocampus and amygdala with subsequent spreading of tau pathology to neocortical and subcortical regions. Accumulated, sarcosyl-insoluble tau was found to be phosphorylated, ubiquitinated, and stainable with the Gallyas silver impregnation method [40] . Again, in analogy to the P301S mouse model reported by Bellucci et al. [5] , a pronounced activation of microglia was prominent. Behavioral tests of the R406W tg mice revealed motor symptoms as well as progressive loss of acquired memory at the age of 10-12 months [40] . In a third tg human tau R406W mouse strain, with expression driven by the MoPrP promoter, Zhang et al. [98] similarly observed Wlamentous tau lesions with advancing age, which occurred in neuronal perikarya of the cerebral cortex, hippocampus, cerebellum, and spinal cord. Interestingly, when compared to otherwise identical tg mice expressing human wt tau, reduced tau levels were found in CNS axons and linked to retarded axonal transport, presumably resulting from an accumulation of insoluble R406W but not human wt tau protein [98] . In yet another model, where G272V and P301S mutations were coexpressed in a thy-1.2-regulated manner, hyperphosphorylation and Gallyas-positive NFTlike pathology were observed. These mice developed defective hippocampal synaptic transmission as well as behavioral and cognitive abnormalities such as increased anxiety, learning deWcits, and impaired spatial memory [73] . Finally, Lim et al. [54] reported on a tg mouse model expressing human triple mutant tau under control of the murine thy-1 promoter. All of these mutants (G272V, P301L, and R406W) have been found in FTDP-17T kindreds [39] . Transgenic expression of this triple mutant at relatively low levels led to Wbrillar, hyperphosphorylated tau pathology in neurons, in particular of cortical and hippocampal regions. Transgene expression was low in the spinal cord, and no obvious motor deWcits were observed up to 12 months [54] .
In summary, in mouse lines engineered to express FTDP-17T-associated missense mutations, abundant Wlaments containing hyperphosphorylated tau protein developed, which was associated with neuronal cell loss. The fact that phosphorylation was observed in soluble tau points to the fact that hyperphosphorylation is likely to occur prior to Wlament assembly. Indeed, as demonstrated [63] , an increase in tau phosphorylation in the soluble tau fraction may result in increased Wlament formation, indicating that phosphorylation of tau plays a contributory, if not causal role in the process of tau self-aggregation [63] . However, one crucial question that has not been answered yet in vivo is whether tau phosphorylation represents a primary event or occurs secondarily to the tau protein undergoing subtle conformational (pathological) changes.
Modeling glial pathology
Finally, two tg models where FTDP-17T mutations were expressed to model glial tau pathology, shall be brieXy mentioned here. In the Wrst approach, Götz et al. [30] expressed the human G272V mutation with a MoPrP promoter-autoregulatory tetracycline-dependent transactivator system and found transgene expression in neurons as well as oligodendrocytes. Although formation of Wlamentous tau associated with phosphorylation of the protein was observed, these mice did not develop any obvious neurological deWcits [30] . In yet another P301L tg mouse strain with transgene expression regulated by an oligodendrocytespeciWc promoter [2Ј,3Ј-cyclic nucleotide 3Ј-phosphodiesterase (CNP)], Higuchi et al. [36] demonstrated the mutant tau in CNS oligodendrocytes to become insoluble and Wlamentous at 15 months of age. In these mice, disruption of myelin and axonal degeneration occurred, and subsequent motor deWcits developed. Finally, coiled body-like NFT formation in oligodendrocytes was also revealed in tg P301L mice (MoPrP promoter) described earlier [53, 55] . Double and triple transgenic mice as models for AD pathogenesis ( Table 2) Alzheimer's disease is neuropathologically characterized by two signature lesions, extracellular plaque-like deposition of A as well as intracellular formation of NFTs containing hyperphosphorylated tau. Despite several decades of research eVorts, it is still not known whether or not both pathologies are causally related to each other. According to the amyloid cascade hypothesis [32] , and possibly in the reality of AD, they are in that A is likely to function upstream to trigger tau pathology. Along these lines, A oligomers have recently been shown to impair proteasome activity, thereby enhancing tau accumulation [89] . Moreover, APP mutations are causally linked to early onset forms of AD, but no tau mutations have ever been linked to the disease. However, at least outside the context of AD, the general validity of the hypothesis can be questioned by a number of observations. First, in PSP, CBD, AgD, and FTDP-17T, neurodegeneration occurs in the absence of A pathology. Second, it is interesting to note that tg mutant APP mice, despite showing extensive parenchymal and vascular amyloid pathology, do not develop robust tauopathyrelated changes (see review by van Leuven [91] ). Furthermore, it was recently reported that intraneuronal A immunoreactivity may not be predictive of neuroWbrillary tau pathology [94] . On the other hand, double tg mice, coexpressing mutant APP and the P301L tau mutation develop not only A as well as tau pathology, but also display amyotrophy and severe motor problems [52] . In addition, triple tg mice (3xTg-AD) overexpressing mutant APP (harboring the Swedish mutation), the M146V presenilin-1 mutant, and the P301L mutant tau, exhibit a combined, progressive tau and amyloid pathology [66] . Synaptic dysfunction with deWcits in long-term potentiation manifested prior to the occurrence of plaques and tangles [66] . Interestingly, in this model amyloid deposition precedes NFT formation, consistent with the amyloid cascade hypothesis [65] . Moreover, when proteasome function is blocked in 3xTg-AD mice at a prepathological stage, a marked increase in tau as well as A accumulation ensues [89] . Furthermore, by intracerebrally injecting A 42 Wbrils into P301L mice an increase in NFTs was triggered in the amygdala from where neuronal projections run to the injection sites, which is clearly indicative of a pathogenic link between A and tau [28] .
In another recent approach it was tested whether lowering the expression of endogenous tau could block Ainduced cognitive impairments. To this end, human APP transgenic mice [60] were crossed with tau knockout animals. Remarkably, ablation of endogenous murine tau prevents the A -dependent behavioral deWcits that typically develop in human tg APP mice, without having any measurable eVects on amyloid plaque load [71] . Another important aspect of that same work [71] is that tau may have a role in regulating nerve cell activity and that lowering levels of tau expression might represent a strategy to inhibit hyperexcitability-induced damage of CNS neurons; the underlying molecular correlates of this excitotoxic tau eVect remain to be clariWed.
Therapeutic approaches
So far, available therapeutic approaches have only met with limited success, with only a few approved modalities thatonly transiently-slow cognitive decline [58] . Perhaps, unless the primary cause(s) triggering the neuronal cell death cascade in tauopathies are targeted, there are only modest chances to succeed in developing highly eYcient therapeutic strategies capable of preventing or at least halting the vicious circle of neurodegeneration in these disorders.
According to the amyloid cascade hypothesis, reduction of the culprit A , supposed to act upstream of tau, appears to be an obvious strategy. However, recent reports (e.g. [71] ) indicate that reducing tau may be an equally warranted, eVective, and possibly complementing approach.
A number of additional strategies are conceivable, one of them targeting abnormal tau phosphorylation. The longest adult tau variants contain almost 80 potential serine and threonine phosphorylation sites, although only about 30 of them seem to be functionally relevant under physiological conditions [12] . The phosphorylation status of tau can be modulated by the prolyl-isomerase Pin1 [56] which catalyzes the conversion between two distinct phospho(Ser/ Thr)-Pro motif conformations, thereby perhaps also indirectly promoting tau dephosphorylation. Interestingly, Pin1 knockout mice exhibit progressive, age-dependent motor and behavioral deWcits, accompanied by tau hyperphosphorylation, tau Wlament formation, and neuronal degeneration [56] . Apart from Pin1, in particular three kinases, GSK-3 [57] , CDK5 [63] , and ERK2 [47] have been associated with modulating tau phosphorylation in vivo. Of note, tg mice overexpressing GSK-3 display tau hyperphosphorylation, disrupted microtubules, and apoptotic neurons [57] . Interestingly, conditional expression of dominantnegative GSK-3 (unexpectedly, the constitutive GSK-3 knockout is embryonically lethal due to massive apoptosis in the liver [37] ), leads to increased neuronal apoptosis and motor symptoms, both of which are suppressed when transgene expression is switched oV [25] . In another experimental approach, the administration of an orally bioavailable, blood-brain barrier-penetrating small molecule inhibitor of ERK2 to tg P301L mice was eVective not only at signiWcantly reducing hyperphosphorylated tau but also in preventing the typical motor deWcits in these animals. Remarkably, however, there was no concomitant reduction of NFTs, suggesting that tau cytotoxicity is not so much exerted by NFTs but may rather be caused by smaller tau aggregates. The prevention of hyperphosphorylation through inhibition of one of the tau-phosphorylating kinases may also point to a crucial pathogenic role of dysregulated tau phosphorylation in tauopathies [47] .
However, CDK5, ERK2, and GSK-3 also function to regulate various important physiological pathways, necessitating the design of kinase inhibitors that eVectively suppress tau hyperphosphorylation while showing only minimal toxicity through oV-target eVects. If successful, such kinase inhibitors (recently reviewed in [59] ) might yield a valuable adjunct to currently available treatment options.
In addition, administration of lithium-chloride, a drug traditionally used in the treatment of bipolar disorders, has recently been shown not only to inhibit GSK-3 activity but also to result in decreased tau pathology [62] , which strongly correlated with markedly reduced axonal degeneration in P301L tg mice [64] . Other alternative (although currently more theoretic) approaches could be aimed at preventing the proteolytic cleavage-mediated generation of small, nucleation-promoting tau fragments through inhibition of speciWc proteases such as calpain or caspases [15, 35] . Stabilizing microtubules might represent another potential therapeutic avenue (for review see [87] ). Agents with respective activity, in particular taxols such as paclitaxel are commonly used in cancer treatment (recently reviewed in [45] ). As they act on dividing cells, adverse eVects are hard to be avoided. Nevertheless, treatment of tg mice expressing the 3R/0N isoform of human wt tau with paclitaxel resulted not only in the restoration of fast axonal transport but also led to the improvement of motor deWcits [99] . Finally, as A oligomers were recently demonstrated to enhance tau accumulation through impaired proteasome activity, the proteasome appears to be another attractive target for therapeutic intervention [89] .
Open questions
Admittedly, despite decades of intense research, many of the central questions underlying the pathogenic mechanisms in tauopathies still remain unanswered. In particular, the nature of the triggering event(s) initiating tau aggregation in vivo remains enigmatic. One of the questions that arises in that context is whether tau phosphorylation is a general prerequisite for Wlament formation and if so, how both processes are linked. To what extent are the nucleation-promoting eVects mediated by smaller, proteolytically derived tau fragments important events in Wlamentous aggregation? If the amyloid cascade hypothesis is correct, what are the mechanisms of A triggering tau Wlament assembly? Which species of tau are the toxic ones? Do Wlamentous tau aggregates even act in a protective way by promoting the sequestration of the toxic species? Finally, what is the role of inXammation related to the development of tau pathology? What is the basis for the AD-stage-speciWc spatio-temporal distribution of tau lesions?
Conclusions
Despite the fact that the available animal models cannot suYciently mirror the complex pathogenesis of human tauopathies, they will continue to provide important new insights into the molecular pathways at play in these disorders. In particular, genetically engineered mouse models will continue to lead the way in tauopathy research. Rather than completely reXecting the entire pathogenic process with all its diVerent aspects, they can be used to adequately recapitulate crucial aspects of these disorders. One of their particular strengths is that, even under the highly artiWcial conditions of transgene overexpression, our comprehension/understanding of tauopathies can be further expanded by studies of protein interactions as well as of induced protein modiWcations and their consequences. Last but not least, using worms and Xies may pay oV as well, e.g., in high-throughput drug-screens which may lead to the identiWcation of agents that lend themselves for the designing of novel therapeutic strategies for these devastating diseases.
